Background Standard treatment options for patients with advanced gastric or
gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some …

Despite a decrease in incidence over past decades, gastric cancer remains a major global
health problem. In the more recent period, survival has shown only minor improvement …

Gastric cancer is a common neoplastic disease and, more precisely, is the third leading
cause of cancer death in the world, with differences amongst geographic areas. The …

Background Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown
antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor …

Esophageal cancers are highly aggressive tumors with poor prognosis despite some recent
advances in surgical and radiochemotherapy treatment options. This study addressed the …

Gastric cancer is one of the main causes of cancer-related deaths worldwide. Even when
diagnosed as a localized disease and resected with the intent to cure, recurrences …

Abstract Forkhead box k1 (FOXK1) is a member of the FOX class of transcription factors and
it is dysregulated in many solid tumors including hepatocellular carcinoma, gastric cancer …

Fibroblast growth factor receptors (FGFRs) regulate a variety of cellular functions, from
embryogenesis to adult tissue homeostasis. FGFR signaling also plays significant roles in …

Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor
activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction …

Gastric cancer is a common malignant tumor originating from the gastric mucosa epithelium.
Studies have shown that bioactive substances such as antimicrobial peptides and …